| PRECLINICAL | evidence | Semaglutide and health risk: Development and validation of a LC-HRMS method for testing semaglutide in whole blood and application to real cases. | Ozempic | — | 2024-07-15 |
| PRECLINICAL | evidence | The association between weight loss medications and cardiovascular complications. | Ozempic | — | 2024-07-01 |
| PRECLINICAL | evidence | Daily briefing: How obesity drugs like Ozempic create a full feeling. | Ozempic | — | 2024-06-28 |
| PRECLINICAL | evidence | Does Ozempic boost fertility? What the science says. | Ozempic | — | 2024-06-26 |
| PRECLINICAL | evidence | Daily briefing: Cheaper versions of drugs like Wegovy are on their way. | Wegovy | — | 2024-06-19 |
| PRECLINICAL | evidence | Managing the new wave of weight loss medication in general practice: A qualitative study. | Wegovy | Weight & fat loss | 2024-06-01 |
| PRECLINICAL | evidence | A meta-analysis of the incidence of acne vulgaris in patients treated with GLP-1 agonists. | Ozempic | — | 2024-06-01 |
| PRECLINICAL | evidence | Wernicke Encephalopathy Associated With Semaglutide Use. | Ozempic | — | 2024-06-01 |
| PRECLINICAL | evidence | Ozempic keeps wowing: trial data show benefits for kidney disease. | Ozempic | Glycemic control | 2024-06-01 |
| PRECLINICAL | evidence | Out-of-Pocket Costs among Commercially Insured Individuals with type 2 Diabetes and Obesity: Comparison between Ozempic and Sleeve Gastrectomy. | Ozempic | — | 2024-05-22 |
| PRECLINICAL | evidence | Time to unshackle the medical treatment of obesity in the NHS. | Wegovy | Weight & fat loss | 2024-05-01 |
| PRECLINICAL | evidence | Dose-dependent erythema nodosum after initiation of semaglutide. | Ozempic | — | 2024-05-01 |
| PRECLINICAL | evidence | Ozempic and dental therapy. | Ozempic | Glycemic control | 2024-05-01 |
| PRECLINICAL | evidence | A new indication for semaglutide (Wegovy). | Wegovy | Glycemic control | 2024-04-29 |
| PRECLINICAL | evidence | Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. | Ozempic | Glycemic control | 2024-04-15 |
| PRECLINICAL | evidence | Interaction of Semaglutide and Ziprasidone in a Patient With Schizophrenia: A Case Report. | Ozempic | — | 2024-04-01 |
| PRECLINICAL | evidence | GLP-1 agonists: A review for emergency clinicians. | Ozempic | — | 2024-04-01 |
| PRECLINICAL | evidence | Appendicitis: A Hidden Danger of GLP-1 Receptor Agonists? | Ozempic | — | 2024-04-01 |
| PRECLINICAL | evidence | AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication. | Ozempic | Gut barrier & GI healing | 2024-04-01 |
| PRECLINICAL | evidence | GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide). | Ozempic | — | 2024-04-01 |
| PRECLINICAL | evidence | Wegovy: FDA approves weight loss drug to cut cardiovascular risk. | Wegovy | — | 2024-03-13 |
| PRECLINICAL | evidence | Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. | semaglutida | — | 2024-03-01 |
| PRECLINICAL | evidence | Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management. | Ozempic | Glycemic control | 2024-03-01 |
| PRECLINICAL | evidence | Willingness to Pay (WTP) for Newer Treatment Options for Diabetes: A Study Among Patients at a Tertiary Care Centre. | Rybelsus | — | 2024-03-01 |
| PRECLINICAL | evidence | Impact of a pharmacist-led weight management service in a cardiology clinic. | Wegovy | Weight & fat loss | 2024-03-01 |
| PRECLINICAL | evidence | Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. | Ozempic | Glycemic control | 2024-02-01 |
| PRECLINICAL | evidence | Effect of semaglutide on weight loss and glycaemic control in patients with Prader-Willi Syndrome and type 2 diabetes. | semaglutida | — | 2024-02-01 |
| PRECLINICAL | evidence | Daily briefing: Drugs such as Ozempic could help with Alzheimer's and Parkinson's. | Ozempic | — | 2024-01-29 |
| PRECLINICAL | evidence | The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review. | Ozempic | — | 2024-01-08 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND). | Ozempic | — | 2024-01-01 |
| PRECLINICAL | evidence | Semaglutide (Ozempic((R))) Use in Denmark 2018 Through 2023 ‒ User Trends and off-Label Prescribing for Weight Loss. | Ozempic | — | 2024-01-01 |
| PRECLINICAL | evidence | Social Media as Pharmacovigilance: The Potential for Patient Reports to Inform Clinical Research on Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Substance Use Disorders. | Ozempic | Glycemic control | 2024-01-01 |
| PRECLINICAL | evidence | Effects of Oral Semaglutide on Renal Function in Diabetic Kidney Disease: A Short-term Clinical Study. | Rybelsus | Glycemic control | 2024-01-01 |
| PRECLINICAL | evidence | Natural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon. | Ozempic | — | 2024-01-01 |
| PRECLINICAL | evidence | The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study. | Ozempic | Glycemic control | 2024-01-01 |
| PRECLINICAL | evidence | Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. | Ozempic | Weight & fat loss | 2024-01-01 |
| PRECLINICAL | evidence | Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future. | Ozempic | — | 2024-01-01 |
| PRECLINICAL | evidence | Elucidating the Degradation Pathways of Human Insulin in the Solid State. | Rybelsus | — | 2024-01-01 |
| PRECLINICAL | evidence | Patient Evaluation and Surgical Staging. | Ozempic | Weight & fat loss | 2024-01-01 |
| PRECLINICAL | evidence | [Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases. | semaglutida | — | 2024-01-01 |
| PRECLINICAL | evidence | Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study. | Ozempic | Weight & fat loss | 2024-01-01 |
| PRECLINICAL | evidence | Semaglutide-associated hyposalivation: A report of case series. | Ozempic | Weight & fat loss | 2023-12-29 |
| PRECLINICAL | evidence | Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs. | Rybelsus | — | 2023-12-28 |
| PRECLINICAL | evidence | Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. | Ozempic | Glycemic control | 2023-12-14 |
| PRECLINICAL | evidence | As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging. | Ozempic | Weight & fat loss | 2023-12-12 |
| PRECLINICAL | evidence | Money being paid for prescribing Wegovy in pilot studies is "over the top," say critics. | Wegovy | — | 2023-12-11 |
| PRECLINICAL | evidence | Corrigendum: Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons. | Ozempic | — | 2023-12-01 |
| PRECLINICAL | evidence | Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons. | Ozempic | Glycemic control | 2023-12-01 |
| PRECLINICAL | evidence | Letter to the Editor: Comment on Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons. | Ozempic | — | 2023-12-01 |
| PRECLINICAL | evidence | Semaglutide: a new drug for the treatment of obesity. | Ozempic | Glycemic control | 2023-11-29 |